Nitin Jain: Update on Pirto Ven and Obin triplet in firstline CLL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in ASH:
“At ASH24, we provide update on Pirto Ven and Obin triplet in firstline CLL.
Data on 80 firstline patients.
High rates of U-MRD6 remission in both blood and marrow.
Oral abstract presentation on Monday of ASH meeting.”
Authors: Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Hagop Kantarjian, William Wierda et al.
More posts featuring Nitin Jain.
Dr. Nitin Jain is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, USA. He leads the CAR T program for the Leukemia Department, MDACC, and received the Leukemia and Lymphoma Society (LLS) Scholar in Clinical Research and Translational Research Program awards in 2022.
Specializing in acute and chronic leukemias, notably CLL and ALL, his research focuses on new drug development, reflected in his leadership of multiple investigator-initiated clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023